Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation

Leukemia

Volumn 26, Issue 6, 2012, Pages 1425-1429

  McDaniel, J M ^a,b   Zou, J X ^b   Fulp, W ^b   Chen, D T ^b   List, A F ^b   Epling Burnette, P K ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE;

CELL ACTIVITY; CHROMOSOME DELETION 5; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LETTER; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNE TOLERANCE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; T-LYMPHOCYTES; THALIDOMIDE;

EID: 84862006649     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.359     Document Type: Letter

References (16)

1. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45-52.
2. Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4 edn. IARC: Lyon, 2008.
3. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974-12979.
4. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-557. (Pubitemid 40204668)
5. Neuber B, Herth I, Tolliver C, Schoenland S, Hegenbart U, Hose D et al. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J Immunol 2011; 187: 1047-1056.
6. Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010; 116: 3227-3237.
7. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118: 2427-2437. (Pubitemid 351949771)
8. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165: 302-319. (Pubitemid 17019817)
9. Czesnikiewicz-Guzik M, Lee WW, Cui D, Hiruma Y, Lamar DL, Yang ZZ et al. T cell subset-specific susceptibility to aging. Clin Immunol (Orlando, Fla.) 2008; 127: 107-118.
10. Fagnoni FF, Vescovini R, Mazzola M, Bologna G, Nigro E, Lavagetto G et al. Expansion of cytotoxic CD8+ CD28-T cells in healthy ageing people, including centenarians. Immunology 1996; 88: 501-507. (Pubitemid 26255117)
11. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7-CD28-T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996; 97: 2027-2037. (Pubitemid 26143956)
12. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000; 1: 426-432.
13. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332: 143-149.
14. Mackall CL, Gress RE. Thymic aging and T-cell regeneration. Immunol Rev 1997; 160: 91-102. (Pubitemid 28021369)
15. Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Medicine 2008; 5: e35.
16. List AFWK, Knight R. Transfusion burden, disease duration and age identify non-deletion 5q MDS patients highly responsive to lenalidomide treatment. 13th Congress of the European Hematology Association; 2008; Copenhagen, Denmark: Haematologica; 2008.